The Centers for Medicare & Medicaid Services March 7 invited drug makers in the Medicaid Drug Rebate Program that make federally approved gene therapies for sickle cell disease to apply through May 1 to participate in the Cell and Gene Therapy Access Model. Announced in January, the model will negotiate rebate agreements with participating drug makers in an effort to increase access to treatments for Medicaid patients with rare and severe diseases, beginning with sickle cell disease. CMS expects states to apply this summer to participate in the voluntary model, which may also include the Children’s Health Insurance Program, depending on state and manufacturer interest.  
 

Related News Articles

Headline
The Centers for Medicare & Medicaid Services March 28 announced an extension of its temporary Marketplace special enrollment period for those who lost…
Headline
The Centers for Medicare & Medicaid Services March 27 finalized a rule proposed in 2022 to standardize Medicaid and CHIP enrollment and renewal processes…
Headline
The Centers for Medicare & Medicaid Services March 15 announced flexibilities to help states initiate interim Medicaid payments to health care providers…
Headline
The Senate voted 75-22 on March 8 to pass and send to the president for his signature a package of six appropriations bills funding certain federal agencies…
Headline
The House March 6 voted 339-85 to pass a package of six appropriations bills that would fund certain federal agencies through fiscal year 2024 and contains…
Headline
The House and Senate Appropriations Committees March 3 released a package of six appropriations bills that would fund certain federal agencies through fiscal…